Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial Lancet Oncol
MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis Nat Cell Biol
Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications FRONT MED-LAUSANNE
NOX2 control over energy metabolism plays a role in acute myeloid leukaemia prognosis and survival FREE RADICAL BIO MED
Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors Mol Cancer
Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development Front Immunol